Apeiron release date

Author: r | 2025-04-25

apeiron release date Bnb XRP Eth crypto futures coinbase futures. Popular futures. Tags. apeiron investment group apeiron release date 2025 coin release dates a sol release date abyss world release date ada cardano goguen release date ada dental records release form ada masali 6 release date ada smart contract release time ada smart contracts PRESS RELEASE Apeiron Biologics Establishes Biotech-Spinoff Attoquant Diagnostics Vienna, : APEIRON Biologics AG (Apeiron) today announced the Apeiron started operations in 2025 and has 23 employees as of today. About Attoquant (as of December 2025): Created Date:

Apeiron (2025) - Release Dates - The Movie Database (TMDB)

Laying all the foundations for the new marketplace, as well as getting ready various elements for our PvP mode. Now that the migration has started and the new Marketplace has successfully gone live, the team will be moving all hands on deck for getting ready S3 content.Speaking of S3 content, the design team has returned to revamping our dungeon mechanics, level design, and adjusting the battle, event and drop systems. With so many updates underway, players can anticipate a ton of new features for the next release. We’re particularly excited for you guys to get your hands on the new hot pot system. It’s both cute, food-related, and provides an easy way to power up your team!A delicious dood favoriteSince the inception of Apeiron, our whitepaper has existed as a comprehensive guide to everything about our game. As our vision has evolved over time, and given that the migration is happening with the new Marketplace this month, now seemed like the perfect time to roll out an update — so we did! The newest version of the whitepaper reflects the most up to date info on the game, and we’ve also improved its readability for newcomers, making it more beginner-friendly and gameplay focused.If you want to know all the nitty gritty details about Apeiron, you can find all of them in the whitepaper — here.The story team has been working on the main storyline for the S3 beta release with the artists for several months, and now it’s nearly done, they’re topping it with some detailed character animations. Throughout the story, you’ll see different godly characters acting elegant and majestic, thanks to our 3D artists. They’re paying extra attention to the movements of each character, down to their bones even. With every bow and every smile, their etiquette surely reflects the glory of the godiverse. And uh, hey, there seems to be something moving in the box! What’s that? Oh, it’s confidential for now.A god…Do you know him?Every month we tell one to two story or lore pieces about the godiverse on our medium, and for this month, we’ve made

Release date of Apeiron in different countries around the world

Public conference calls and webcasts.Adjusted Financial MeasuresLigand reports adjusted earnings per share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Ligand’s financial measures under GAAP include share-based earnings expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based earnings, income tax effect of adjusted reconciling items and others. However, Ligand does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, changes in the market value of its investments in public companies, share-based compensation expense and the effects of any discrete income tax items. Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing Ligand’s past and future core operating performance. Additionally, adjusted earnings per diluted share is a key component of the financial metrics utilized by Ligand’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation.Forward-Looking StatementsThis news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding: the timing of the anticipated acquisition and when and whether the anticipated acquisition ultimately will close; the potential contributions the acquisition is expected to bring to Ligand, including technologies, collaborations and revenue streams, the potential to secure additional licenses, and development operations; and the expected impact on Ligand’s future financial and operating results. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherent in Ligand’s business, including, without limitation: the risk that the conditions to the closing of the transaction are not satisfied; litigation relating to the transaction; uncertainties as to the timing of the consummation of the transaction and the ability of each of Ligand or APEIRON to consummate the transaction; risks that the proposed transaction disrupts the current and future plans and operations of Ligand or APEIRON; whether the acquisition will be immediately accretive to Ligand’s earnings per

The Apeiron Project - release date, videos, screenshots, reviews

Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the beginning of 2023Transaction will be immediately accretive to Ligand EPS by an estimated $1.00 per share on an annualized basis with a $0.50 impact to 2024Ligand increases 2024 adjusted EPS guidance range by 17% to $5.00-$5.501 Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively.APEIRON is a private biopharmaceutical company based in Vienna, Austria. The company co-developed QARZIBA for the treatment of high-risk neuroblastoma in patients aged 12 months and above. QARZIBA was approved by the European Medicines Agency in 2017 and is commercially available today in more than 35 countries. APEIRON receives an undisclosed royalty on net sales of QARZIBA outside of mainland China from Recordati S.p.A, a leading global pharmaceutical company with a presence in over 150 countries and sales of more than $2.2 billion,2 and on net sales of QARZIBA within mainland China from BeiGene, Ltd.“The addition of QARZIBA to our commercial royalty portfolio further supports our growth strategy to invest in high-value medicines that deliver significant clinical value and generate predictable and long-term revenue streams for our investors,” said Todd Davis, CEO of Ligand. “QARZIBA is the only immunotherapy for high-risk neuroblastoma marketed across Europe and in other parts of the world. We believe this drug will be a meaningful contributor to our royalty revenue, which is now driven by a diversified portfolio of 12 key commercial-stage products.”Peter Llewellyn-Davies, CEO of APEIRON commented, “This transaction is an important milestone for our company and shareholders. We have spent more than 20 years translating academic research into therapeutic products for diseases with high unmet needs. Our team was honored to help bring QARZIBA to the young patients who need it. We appreciate that Ligand recognizes the long-term potential of this critical drug for a rare pediatric cancer.”Transaction TermsUnder the terms of the agreement, which has. apeiron release date Bnb XRP Eth crypto futures coinbase futures. Popular futures. Tags. apeiron investment group apeiron release date 2025 coin release dates a sol release date abyss world release date ada cardano goguen release date ada dental records release form ada masali 6 release date ada smart contract release time ada smart contracts PRESS RELEASE Apeiron Biologics Establishes Biotech-Spinoff Attoquant Diagnostics Vienna, : APEIRON Biologics AG (Apeiron) today announced the Apeiron started operations in 2025 and has 23 employees as of today. About Attoquant (as of December 2025): Created Date:

Apeiron Idis MAP Release Final - APEIRON Biologics

Apeiron 01 – TRANSMISSION I02 – AWAKENING03 – SCHWINGER EFFECT04 – TEMPORAL PARADOX05 – APEIRON (PART I & II )06 – FLOW OF ORDER07 – BOUNDLESS08 – WAITING ON INFINITY09 – TRANSMISSION II (FEAT. PAT KEISTA)10 – BEYOND APEIRONRELEASE: 14 OCTOBER, 2023(excerpt) When Ron Boots gets excited and carried away, we have to be curious. And when he praises an artist, his music. We have to listen! The man’s knowledge of electronic music (EM) is immense, and his knowledge of the art, as he plays and produces it, has built his credibility over the years.Terminus Void’s APEIRON is the reason for the Groove.nl boss’ latest enthusiasm. Since the album is available on the famous Dutch label, is this a cultural conflict of interest? Yes and no! Yes, because it is! And no, because Ron is absolutely right! In a musical envelope with an essence of sonic renewal, APEIRON brings you a hefty 65 minutes of EM that breathes the analog years while throwing into the ambiences those futuristic visions with the unique tones of Vangelis. In short, a unique blend thanks to the use of the Waldorf Quantum synthesizer, which harmonizes the sounds of the analog era with the more contemporary sounds of digital synthesizers. The imprint and influences of the Greek keyboard wizard are everywhere in APEIRON, so much so that the Seattle musician-synthesist multiplies floating harmonies and arrangements in a tonality that is very close to the Greek legend. Sharp blades of lament and rotating waves that make apocalyptic sirens wail are legion on this album, flirting with Papathanassíou’s cosmic, sci-fi dimensions. Not only is the music beautiful, with a seductively warm imprint, the rhythms are in evolutionary mode, with a sequencer that can structure up to 3 lines of sequences in a single track. The beginnings are often quiet, evolving into catchy down tempos, and ultimately good rock and/or cosmic Berlin School. Electronic percussions underpin the sequenced rhythms with attractive textures. You’re free to read the long, very detailed review that follows… if not, this APEIRON is a must if you like creative, harmonious and catchy progressive cosmic EM.Sylvain Lupari (November 1st, 2023)Read the full review here: Synth&Sequences

Apeiron - what kind of game is it, release date, trailer and videos

Been unanimously approved by both the Board of Directors at Ligand and APEIRON’s Supervisory Board, Ligand will acquire all the outstanding shares of APEIRON for $100 million in cash at closing. Ligand will also pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. The transaction is subject to a 30-day shareholder objection period and other customary closing conditions and is expected to close in July 2024.Concurrently, Ligand is also entering into a stock purchase agreement whereby it has committed to investing up to $4 million in invIOs Holding AG, a privately held spin-off of APEIRON. The proceeds will help finance the research and development of three innovative early-stage immuno-oncology assets. APEIRON is entitled to royalties and milestone payments on these assets which will further expand Ligand’s development stage portfolio. This transaction is expected to close in July 2024.Financial Guidance UpdateThe APEIRON acquisition will be immediately accretive to Ligand’s earnings per share (EPS) by approximately $1.00 on an annualized basis. Ligand is increasing its 2024 revenue guidance to be in the range of $140 million to $157 million (previously $130 million to $142 million) and is raising core adjusted EPS guidance to $5.00 to $5.50 (previously $4.25 to $4.75). Royalties are now expected to range from $100 million to $105 million (previously $90 million to $95 million). Guidance for sales of Captisol® is unchanged at $25 million to $27 million and contract revenue is now expected to range from $15 million to $25 million (previously $15 million to $20 million).McDermott Will & Emery and E+H Rechtsanwälte GmbH served as Ligand’s legal counsel. Baker McKenzie represented the APEIRON shareholders and DORDA served as APEIRON’s legal counsel.About QARZIBA® QARZIBA is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Medicines Agency in 2017 for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease.Dinutuximab beta was originally discovered by EMD Lexigen Research Center and ultimately developed by the Children’s Cancer Research Center (CCRI) and

Apeiron Release Information for PC - GameFAQs

Can read more about the migration here.We are eternally grateful for those who took this big leap and continued to support us. It is precisely your continued backing that motivates us to continue doing what we love and channel all of our efforts into creating a memorable gameplay experience for our players. You doods rock!And our community is growing! Since our migration announcement on December 18th, over 6000 new doods have downloaded our game from the official Apeiron site and the Epic store. We are thrilled to welcome everyone and can’t wait to see what the future holds for us.And of course, coming alongside the migration have been a host of celebration events! We’ve had quests on Moku (closed now!), we’ve got free homecoming gifts for migraters, we’ve got new Apostles to mint and free Booty Hours, and we’ve got alpha testing for PvP! So much going on — and still going on! For more details, check out this article.We’ve also got some Expeditions going on! These are our premier staking events for our Planet holders. The Mirrored Soul Nebula Expedition will be beginning its New Year Adventure on Friday, Dec 29th, with users being able to stake Apeiron assets and have a chance to earn ANIMUS, one of our in-game tokens.But as it’s a celebration, EVERYONE who stakes will get (1) a redemption code for a Doodelic Wings free mint item and (2) a redemption code for 6 Booty Hours. If you haven’t already, head over to the Marketplace and stake your Planets and Apostles! The sooner you stake, the more chances you have to win rewards.And later on — in mid Jan — we’ll be hosting our Foonie Mavis Expedition, a special Expedition to celebrate the Apeiron x Axie collaboration, in which users will be able to stake to win actual Star NFTs — the land in Apeiron — and a very rare reward indeed! For more information on the Mirrored Soul Nebula Expedition, and the Foonie Mavis Nebula Expedition, you can refer to this article.For the last month (and change), our programmers have been busy as bees

Apeiron (2025) - Release info - IMDb

As December draws to a close, it’s time for Christmas, New Years celebrations, and our last development report of 2023!What a month it’s been: this month, Apeiron officially announced our partnership with Sky Mavis and migration to the Ronin Blockchain, marking the beginning of a new chapter (and a brand new marketplace!). I’m sure that there are some new godlings reading this right now. Let us just say: Welcome!Every month, at the end of the month, we publish a development report to update our community on our working progress. You can find it — as well as many other game updates, news, interviews, stories, and lore pieces — right here, on our medium.Before we dive in, a quick reminder that our PvP Demo Party Night is TONIGHT! Jump into our Discord and let’s get wiiilllddddd.Alright, so now let’s recap what’s happened the last month and what we’re prepping for in the New Year! It’s been hella busy, but we’re thrilled to see the positive reception and attention Apeiron has been getting😇Table of Contents:TGE and $ANIMA BattledropsPreparing for the TGEAnima Battledrop InfoThe Ronin MigrationMarketplace and Asset MigrationHoliday Celebration EventsOngoing ExpeditionsDev UpdatesBackend: Supporting the MigrationStreamlining the DungeonWhitepaper UpdateA more Cinematic Design ApproachDoodmas: Apeiron LoreWe begin with a couple of important announcements of things coming after the New Years…Our TGE is on the way! With this marquee event, we’ll be launching Apeiros ($APRS), our core ecosystem ERC20 token tradeable on CEX and the Katana DEX. $APRS will be very rare, with a capped supply, but also an essential part of creating NFTs and expanding the Apeiron ecosystem. If you want to have a defining role in the future of Apeiron, get some $APRS through our community round in January!So who can participate in the community round? First, our Primeval Planet holders — which is to say, holders of the first Planets ever to be made — will have allocation for purchasing $APRS. The exact amount to be allocated per holder will depend on the total number of Primeval Planets held as well as the exordium type and age of those Planets. Second, our. apeiron release date Bnb XRP Eth crypto futures coinbase futures. Popular futures. Tags. apeiron investment group apeiron release date 2025 coin release dates a sol release date abyss world release date ada cardano goguen release date ada dental records release form ada masali 6 release date ada smart contract release time ada smart contracts PRESS RELEASE Apeiron Biologics Establishes Biotech-Spinoff Attoquant Diagnostics Vienna, : APEIRON Biologics AG (Apeiron) today announced the Apeiron started operations in 2025 and has 23 employees as of today. About Attoquant (as of December 2025): Created Date:

Apeiron Idis MAP Release Final

It to the Doodmas celebration. If you’re curious about dood lives and the godiverse, remember to read our stories! Perhaps you might meet some characters before they appear in the game…?“Free hot koko for the winner!”And there you have it! A few months back I promised you updates and now I’ve delivered. It’s time for me to return to work. We’re incredibly excited about the next release and have a feeling that you guys will have as much fun playing as I did. In the meantime, hold on tight! Soon, we’ll be taking off to the godiverse and arrive at 1 Axis Mundi Street! Remember to follow us on our Twitter and Discord for our latest announcements! Happy Holidays and wishing y’all all the best in the coming year!As always, thank you for reading godlings tata~About ApeironApeiron is the world’s first NFT-based play-and-earn god game. Apeiron will feature a unique card-based action-adventure combat system combined with god game simulation gameplay inspired by classic god games like Populous and Black & White. Players will be able to build up planets from above before descending to the ground as a powerful Avatar to solve the mysteries of the universe. Players will grow their planet to the point of developmental stagnation, then reset the planetary cycle via an Armageddon event to allow for even more advancement and thrilling late-game alliance level GvE and GvG activities. Apeiron will use a tri-token architecture, which means that there will be three separate tokens to navigate their ecosystem: a governance token, a play-to-earn token, and a premium alliance token.Visit Apeiron’s Website | Official Marketplace | OpenSea | Youtube | Discord | TwitterDiscussion about this post

Apeiron Release Information for Macintosh - GameFAQs

European Neuroblastoma Research Network (SIOPEN) for the treatment of high-risk neuroblastoma. APEIRON in-licensed dinutuximab beta from CCRI and SIOPEN in 2011, and upon completing the clinical development, out-licensed the exclusive global commercialization rights to EUSA Pharma (UK) Limited in 2016. QARZIBA is marketed outside of mainland China by the global pharmaceutical company Recordati S.p.A., which acquired EUSA Pharma (UK) Limited in 2022.About APEIRON Biologics AGAPEIRON Biologics is a private biopharmaceutical company based in Vienna, Austria. The company co-developed QARZIBA® (dinutuximab beta), a high-risk neuroblastoma drug, which it licensed to EUSA Pharma (UK) Limited (now a Recordati S.p.A. company) in 2016. APEIRON is entitled to an undisclosed royalty on global net sales of QARZIBA. The company also maintains a portfolio of more than 400 patents including the intellectual property and licenses for an early-stage immuno-oncology portfolio currently being developed by invIOs Holding AG which was spun-off from APEIRON in 2022. For more information visit www.apeiron-biologics.com.About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings,. apeiron release date Bnb XRP Eth crypto futures coinbase futures. Popular futures. Tags. apeiron investment group apeiron release date 2025 coin release dates a sol release date abyss world release date ada cardano goguen release date ada dental records release form ada masali 6 release date ada smart contract release time ada smart contracts

Apeiron International Releases - Giant Bomb

This is a list of games on PCGamingWiki marked as being available for purchase on ZOOM Platform. Game Series Developer Publisher First release Available on 1812: Napoleon Wars First Games Interactive First Games Interactive, Immanitas Entertainment October 17, 2019 3D Body Adventure Knowledge Adventure Knowledge Adventure, Jordan Freeman Group December 27, 1993 3D Dinosaur Adventure Dinosaur Adventure Knowledge Adventure Knowledge Adventure, Jordan Freeman Group January 1, 1994 688(I) Hunter/Killer Jane's Combat Simulations Sonalysts Combat Simulations Electronic Arts, Funbox Media, Strategy First June 27, 1997 7.62 Hard Life Brigade E5 HLA team 1C Company, 1C Entertainment, Fulqrum Publishing October 1, 2015 7.62 High Calibre Brigade E5 Apeiron 1C Company, 1C Entertainment, Fulqrum Publishing August 24, 2007 A Stroke of Fate: Operation Bunker A Stroke of Fate SPLine Games Akella October 21, 2009 A Stroke of Fate: Operation Valkyrie A Stroke of Fate SPLine Games Akella February 13, 2009 A Tale of Two Kingdoms Crystal Shard July 16, 2007 A Vampyre Story A Vampyre Story Autumn Moon, Jordan Freeman Group Focus Home Interactive, Crimson Cow, Strategy First, Autumn Moon, Jordan Freeman Group December 2, 2008 A.I.M. 2: Clan Wars A.I.M. SkyRiver Studios 1C Company, 1C Entertainment, Fulqrum Publishing February 17, 2006 A.I.M. Racing A.I.M. SkyRiver Studios 1C Company, 1C Entertainment, Fulqrum Publishing February 9, 2007 A.I.M.: Artificial Intelligence Machines A.I.M. SkyRiver Studios 1C Company, 1C Entertainment, Fulqrum Publishing, Andrico, Micro Application February 27, 2004 Aboo Plumeboom Fireglow Games April 4, 2007 Across the Rhine MPS Labs MicroProse, Night Dive Studios, Retroism, Atari, iEntertainment Network July 1, 1995 Actua Golf 2 Actua Golf Gremlin Interactive Gremlin Interactive, Urbanscan September 1, 1997 Actua Ice Hockey 2 Actua Ice Hockey Gremlin Interactive Gremlin Interactive, Urbanscan, Pixel Games UK April 23, 1999 Actua Pool Actua Sports Gremlin Interactive Gremlin Interactive, Urbanscan January 1, 1999 Actua Soccer